Please login to the form below

Not currently logged in
Email:
Password:

Amgen poaches J&J’s Ray Jordan for corporate affairs post

He joins on October, 1 with a strategic communications remit

Amgen has appointed Ray Jordan to fill the newly created position of senior vice president of corporate affairs.

He will join the US biotech on October, 1 from Johnson & Johnson, where he has served as communications leader with responsibility for corporate comms and public affairs since 2003.

Prior to joining J&J, Jordan was vice president of communications and information for Pfizer, where he held a range of positions over the course of 17 years.

He has also served as chair of PhRMA's public affairs section and, earlier in his career, as a reporter for a regional daily newspaper as well as holding positions with Bristol-Myers and business information company Dun & Bradstreet.

In his new role Jordan will be responsible for strategic communications across Amgen, including internal and external communications, issues management and philanthropy, and report directly to Robert Bradway, Amgen's president and CEO.

Bradway said: "We are very pleased to have Ray join Amgen. He is a strategic thinker and communicator with skills honed at two respected global health care companies.

“Ray's background in both business management and communication will serve Amgen well as we execute on our strategy to deliver results for both patients and shareholders."

12th September 2012

From: Marketing

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cello Health Consulting

Impressive real world experience and expertise fused with process and fresh perspective to unlock opportunities for you, your brand and...

Latest intelligence

Harnessing complexity
Companion diagnostics in oncology...
"Not Another Boring Survey?"
Winning over HCPs… How to Increase Participant Engagement in Healthcare Market Research...
What pharma needs to know about genomic data in 2016
Consultant David Cooney from Blue Latitude Health talks us through what this progress in genomics means for pharma in 2016....

Infographics